Plasma VEGF levels in breast cancer patients with and without metastases

Stathopoulos,J.; Armakolas,A.; Gomatos,I. P.

doi:10.3892/ol_00000129

Plasma VEGF levels in breast cancer patients with and without metastases

Authors:
- J. Stathopoulos
- A. Armakolas
- I. P. Gomatos
View Affiliations

Affiliations: First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000129
Pages: 739-741

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis since it stimulates the formation of new blood vessels. Basic fibroblast growth factor (bFGF) is related to the promotion of endothelial cells into tube-like structures, and it is therefore expected to promote angiogenesis with a greater potency than VEGF. VEGF and bFGF are considered to be biomarkers that predict treatment effectiveness. Elevated plasma VEGF and bFGF levels have been reported in a variety of different malignant tumors, and patients with metastatic disease have also been reported to present with higher serum VEGF and bFGF levels. Other studies have documented controversial results with respect to the prognostic and predictive value of the aforementioned biomarkers. This study aimed to determine the plasma VEGF and bFGF levels in breast cancer patients without metastatic disease compared with breast cancer patients with advanced metastatic disease. The study included 93 patients with breast cancer, 46 without recurrent disease (group A) and 47 with metastatic disease (group B), as well as 21 healthy individuals. The median age was 58 years (range 34-78) for group A and 59 years (range 37-75) for group B. All 93 patients underwent chemotherapy, adjuvant for group A, and adjuvant plus chemotherapy for group B patients with advanced disease. Plasma VEGF and bFGF levels were determined using a quantitative sandwich immunoassay, and samples were tested in triplicate (ELISA). The plasma levels of VEGF and bFGF varied greatly, i.e., from extremely low to extremely high in the two groups, as well as in the healthy individuals. No statistically significant difference was found between the two groups or between the patients and healthy individuals. Data of the present study therefore showed that VEGF and bFGF levels are not valuable biomarkers for predicting treatment outcome.

View Figures

View References

1	Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology. 69(Suppl 3): 4–10. 2005. View Article : Google Scholar : PubMed/NCBI
2	Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997. View Article : Google Scholar
3	Ferrara N, Gerber HP and Le Couter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
4	Ferrara N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 280:C1358–C1366. 2001.PubMed/NCBI
5	Ferrara N: Vascular endothelial growth factor as target for anticancer therapy. Oncologist. 9(Suppl 1): 2–10. 2004. View Article : Google Scholar
6	Shweiki D, Itin A, Soffer D and Kesdet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:843–845. 1992. View Article : Google Scholar : PubMed/NCBI
7	Popovici C, Roubin R, Coulier F and Birnbaum D: An evolutionary history of the FGF superfamily. Bioessays. 27:849–857. 2005. View Article : Google Scholar : PubMed/NCBI
8	Bottcher RT and Niehrs C: Fibroblast growth factor signaling during vertebrate development. Endocr Rev. 26:63–77. 2005. View Article : Google Scholar : PubMed/NCBI
9	Powers CJ, McLeskey SW and Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr Rel Cancer. 7:165–197. 2000. View Article : Google Scholar : PubMed/NCBI
10	Hayes DF: Prognostic and predictive factors revisited. Breast. 14:493–499. 2005. View Article : Google Scholar : PubMed/NCBI
11	Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23:1010–1027. 2005.PubMed/NCBI
12	Larsson A, Sköldenberg E and Ericson H: Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis. 5:107–110. 2002. View Article : Google Scholar : PubMed/NCBI
13	Potgens A, Westphal H, De Waal R and Ruiter D: The role of vascular permeability factor and basic fibroblast growth factor in tumor angiogenesis. Biol Chem Hoppe-Seyler. 376:57–70. 1995.PubMed/NCBI
14	Relf M, LeJeune S, Scott PA, et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiothophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:963–969. 1997.
15	Agnantis NJ, Goussia AC, Batistatou A and Stefanou D: Tumor markers in cancer patients: an update of their prognostic significance (part II). In Vivo. 18:481–485. 2004.PubMed/NCBI
16	Gasparini G: Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol. 37:97–114. 2001. View Article : Google Scholar : PubMed/NCBI
17	Eppenberger U, Kueng W, Schlaeppi JM, et al: Markers of tumor angiogenesis and protelysis independently define high- and low-risk subsets of node negative breast cancer patients. J Clin Oncol. 16:3129–3136. 1998.PubMed/NCBI
18	Smith K, Fox SB, Whitehouse R, et al: Upregulation of bFGF in breast carcinoma and its relationship to vascular density, estrogen receptor, epidermal growth factor receptor and survival. Ann Oncol. 10:707–713. 1999. View Article : Google Scholar : PubMed/NCBI
19	Yiangon C, Gomm JJ, Coope RC, et al: Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer. 75:28–33. 1997. View Article : Google Scholar : PubMed/NCBI
20	Colomer R, Aparicio J, Montero S, Guzman C, Larrodera L and Cortes-Funes H: Low levels of bFGF are associated with poor prognosis in human breast carcinoma. Br J Cancer. 76:1215–1220. 1997. View Article : Google Scholar : PubMed/NCBI
21	Giantonio BJ, Katalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E 3200. J Clin Oncol. 25:1539–1544. 2007. View Article : Google Scholar
22	Saltz LA, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
23	Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology. 69(Suppl 3): 4–10. 2005. View Article : Google Scholar : PubMed/NCBI
24	Ellis LM and Haller DG: Bevacizumab beyond progression: Does this make sense? Editorial J Clin Oncol. 3:1–3. 2009.